TY - JOUR
T1 - Antiretrovirals inhibit arginase in human microglia
AU - Lisi, Lucia
AU - Laudati, Emilia
AU - Miscioscia, Teresa F.
AU - Dello Russo, Cinzia
AU - Topai, Alessandra
AU - Navarra, Pierluigi
PY - 2016
Y1 - 2016
N2 - Preliminary evidence in an animal model, i.e. primary cultures of rat microglia cells, suggested that some antiretroviral drugs (ARVs), namely darunavir, atazanavir, efavirenz and nevirapine, increase NO production through a mechanism involving the inhibition of arginase (ARG) activity. The present study was conceived to investigate the effects of ARVs on ARG activity in a human experimental model. We compared CHME-5 human microglial immortalized cells under basal conditions with cells exposed to either IL-4, a mix of inflammatory cytokines, or both stimuli given together. We also tested the effects of ARVs on CHME-5 cell lysates after exposure to the above stimuli. Moreover, the interaction between the ARVs and ARG was investigated via computational chemistry. We found that ARVs consistently inhibit ARG activity both in intact and lysed cells. In docking studies, darunavir and atazanavir showed similar scores compared with both L-arginine and the ARG antagonist nor-NOHA. Efavirenz and nevirapine, which are less potent in inhibiting ARG in the biochemical assay, also had lower scores. In conclusion the present findings in a human model support the notion that ARG pathway can present a new, additional molecular target for different ARVs in HIV treatments. This article is protected by copyright. All rights reserved.
AB - Preliminary evidence in an animal model, i.e. primary cultures of rat microglia cells, suggested that some antiretroviral drugs (ARVs), namely darunavir, atazanavir, efavirenz and nevirapine, increase NO production through a mechanism involving the inhibition of arginase (ARG) activity. The present study was conceived to investigate the effects of ARVs on ARG activity in a human experimental model. We compared CHME-5 human microglial immortalized cells under basal conditions with cells exposed to either IL-4, a mix of inflammatory cytokines, or both stimuli given together. We also tested the effects of ARVs on CHME-5 cell lysates after exposure to the above stimuli. Moreover, the interaction between the ARVs and ARG was investigated via computational chemistry. We found that ARVs consistently inhibit ARG activity both in intact and lysed cells. In docking studies, darunavir and atazanavir showed similar scores compared with both L-arginine and the ARG antagonist nor-NOHA. Efavirenz and nevirapine, which are less potent in inhibiting ARG in the biochemical assay, also had lower scores. In conclusion the present findings in a human model support the notion that ARG pathway can present a new, additional molecular target for different ARVs in HIV treatments. This article is protected by copyright. All rights reserved.
KW - ARG
KW - Arginase I
KW - antiretroviral drugs
KW - microglia
KW - microglial polarization
KW - ARG
KW - Arginase I
KW - antiretroviral drugs
KW - microglia
KW - microglial polarization
UR - http://hdl.handle.net/10807/91788
U2 - 10.1111/jnc.13393
DO - 10.1111/jnc.13393
M3 - Article
SN - 1471-4159
VL - 136
SP - 363
EP - 372
JO - Journal of Neurochemistry
JF - Journal of Neurochemistry
ER -